Search research articles
Contact Us
Filters
Showing results (151-160 of 207) with videos related to
Page
of 21
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2021
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Justin Ferdinandus, Wolfgang P Fendler, Andrea Farolfi, et al.
American Journal of Clinical Oncology
|
December 22, 2023
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals
Paul E Wallner, Don C Yoo, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA
John Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study
Evan Y Yu, Vivek Narayan, Giuseppe Esposito, et al.
The Journal of Urology
|
June 25, 2019
<sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 1, 2021
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
Hossein Jadvar, Jeremie Calais, Stefano Fanti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
Phillip H Kuo, Don C Yoo, Ryan Avery, et al.
The Journal of Urology
|
September 17, 2019
Reply by Authors
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are Implemented
Jeremie Calais, Johannes Czernin, Matthias Eiber, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 207) with videos related to
Sort By:
Page
of 21
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2021
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Justin Ferdinandus, Wolfgang P Fendler, Andrea Farolfi, et al.
American Journal of Clinical Oncology
|
December 22, 2023
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals
Paul E Wallner, Don C Yoo, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA
John Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study
Evan Y Yu, Vivek Narayan, Giuseppe Esposito, et al.
The Journal of Urology
|
June 25, 2019
<sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 1, 2021
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
Hossein Jadvar, Jeremie Calais, Stefano Fanti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
Phillip H Kuo, Don C Yoo, Ryan Avery, et al.
The Journal of Urology
|
September 17, 2019
Reply by Authors
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are Implemented
Jeremie Calais, Johannes Czernin, Matthias Eiber, et al.
Page
of 21